As of July 26, 2026, 21 CFR 216.23 lists six substances that can be used through this pathway: Brilliant Blue G, cantharidin for topical use only, diphenylcyclopropenone for topical use only, N-acetyl-D-glucosamine for topical use only, squaric acid dibutyl ester for topical use only, and thymol iodide for topical use only
Contraindications : GLP-1 receptor agonists are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2
While GLP-1 medications do not directly harm these systems, rapid weight loss in seniors can occasionally trigger gallstone formation, and underlying heart arrhythmias may require closer cardiac monitoring
Fatty airways: implications for obstructive disease
For patients who have undergone bariatric surgery, Mounjaro is generally considered only if type 2 diabetes remains an issue or in exceptional cases of significant weight regainand always following a full medical review
Treatment should be discontinued if the glycemic response is inadequate, side-effects are intolerable, other treatments in development prove more effective, and according to patient preference, as indicated by the clinical expert
